ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: EARLY PRURITUS RESPONSES FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0
|
作者：
Stander, Sonja [1 ]
Yosipovitch, Gil [2 ]
Silverberg, Jonathan I. [3 ]
Simpson, Eric L. [4 ]
Sinclair, Rodney [5 ]
Su, John C. [6 ,7 ,8 ]
Kerkmann, Urs [9 ]
Gallardo, William Romero [10 ]
Valdez, Hernan [11 ]
Rojo, Ricardo [12 ]
Biswas, Pinaki [13 ]
Farooqui, Saleem A. [14 ]
机构：
[1] Munster Univ Hosp, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany
[2] Univ Miami, Miller Sch Med, Miami Itch Ctr, Miami, FL USA
[3] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
[4] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[5] Sinclair Dermatol, East Melbourne, Vic, Australia
[6] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Populat Allergy, Parkville, Vic, Australia
[7] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Dermatol, Parkville, Vic, Australia
[8] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Paediat, Parkville, Vic, Australia
[9] Pfizer Pharma GmbH, Global Med Affairs Inflammat & Immunol, Berlin, Germany
[10] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Surrey, England
[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA
[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT USA
[13] Pfizer Inc, Biostat, New York, NY USA
[14] Pfizer Ltd, Clin Dev & Operat, Surrey, England
来源：
ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PT13
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [41] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [42] Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
    Silverberg, Jonathan I.
    Simpson, Eric L.
    Pink, Andrew E.
    Weidinger, Stephan
    Chan, Gary
    Biswas, Pinaki
    Clibborn, Claire
    Guler, Erman
    DERMATOLOGY AND THERAPY, 2025, 15 (02) : 367 - 380
  • [43] Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials
    Bewley, A.
    Thyssen, J. P.
    Chiu, W. S.
    Rojo, R.
    Biswas, P.
    Feeney, C.
    DiBonaventura, M.
    Misery, L.
    Stander, S.
    Cork, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E72 - E73
  • [44] Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: an analysis of JADE-EXTEND (a phase III long-term extension study)
    Shi, V.
    Bhutani, T.
    Deleuran, M.
    Fonacier, L.
    Shumack, S.
    Zhang, F.
    Cameron, M. C.
    Chan, G.
    Valdez, H.
    Yin, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E138 - E138
  • [45] Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial
    Silverberg, Jonathan, I
    Kim, Brian S.
    de Bruin-Weller, Marjolein
    Weidinger, Stephan
    Steinhoff, Martin
    Biswas, Pinaki
    Kerkmann, Urs
    Feeney, Claire
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II31 - II32
  • [46] Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
    Reich, Kristian
    Silverberg, Jonathan I.
    Papp, Kim A.
    Deleuran, Mette
    Katoh, Norito
    Strober, Bruce
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Werfel, Thomas
    Zhang, Fan
    Biswas, Pinaki
    DiBonaventura, Marco D.
    Chan, Gary
    Johnson, Susan
    Farooqui, Saleem A.
    Kerkmann, Urs
    Clibborn, Claire
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2056 - 2066
  • [47] Patient-reported symptoms and quality of life in Australian patients with moderate-to-severe atopic dermatitis following treatment with abrocitinib: A post hoc analysis of JADE clinical trials
    Tan, Fiona
    Sinclair, Rodney
    Nas, Pablo Fernandez Pe
    Murrell, Dedee
    Foley, Peter
    Freeman, Michael
    Su, John
    Eisman, Samantha
    Rubel, Diana
    Spelman, Lynda
    Surian, Christine
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 28 - 28
  • [48] Rapidity of efficacy response with abrocitinib versus placebo and dupilumab in the head-neck region of adults with moderate-to-severe atopic dermatitis in the phase III JADE COMPARE study
    Alexis, A.
    Soong, W.
    de Bruin-Weller, M.
    Barbarot, S.
    Weidinger, S.
    Antinew, J.
    Biswas, P.
    Valdez, H.
    Clibborn, C.
    Yin, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : E41 - E41
  • [49] Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
    Alexis, Andrew F.
    Deleuran, Mette
    Silverberg, Jonathan, I
    Gooderham, Melinda J.
    Farooqui, Saleem A.
    Chan, Gary
    Koppensteiner, Herwig
    Biswas, Pinaki
    Watkins, Melissa
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [50] Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
    Staender, Sonja
    Kwatra, Shawn G.
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Yosipovitch, Gil
    Zhang, Fan
    Cameron, Michael C.
    Cella, Ricardo Rojo
    Valdez, Hernan
    DiBonaventura, Marco
    Feeney, Claire
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (01) : 97 - 107
12345